Brief: Sunoco LP Announces Results of Early Participation in Private Exchange Offers and Consent Solicitations for Outstanding Notes of Parkland Corporation and Extension of the Early Participation Exchange Consideration
21/10/2025 13:05
Oct 21 (Reuters) - Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS ANNOUNCES LATE-BREAKING PRESENTATION OF PHASE 2 EXPLORE-CKD TRIAL OF LORUNDROSTAT AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025 Source text: ID:nGNX8vVV2f Further company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway